O114
Oxandrolone
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C19H30O3
CAS Number:
Molecular Weight:
306.44
EC Number:
200-172-9
UNSPSC Code:
41116107
drug control
USDEA Schedule III; Home Office Schedule 4.2; regulated under CDSA - not available from Sigma-Aldrich Canada
Looking for similar products? Visit Product Comparison Guide
signalword
Danger
hcodes
pcodes
Hazard Classifications
Carc. 2 - Repr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Laura J Porro et al.
Journal of the American College of Surgeons, 214(4), 489-502 (2012-04-03)
Oxandrolone, an anabolic agent, has been administered for 1 year post burn with beneficial effects in pediatric patients. However, the long-lasting effects of this treatment have not been studied. This single-center prospective trial determined the long-term effects of 1 year
Marsha L Davenport
Pediatric endocrinology reviews : PER, 9 Suppl 2, 723-724 (2012-09-06)
Short stature is the single most common physical abnormality in Turner syndrome (TS) with adult stature averaging 20 cm shorter than that of the general population. Randomized, placebo-controlled studies to final adult height have proven that GH therapy is effective
Ana Vládia Ramos Fonteles et al.
Arquivos brasileiros de endocrinologia e metabologia, 55(5), 318-325 (2011-09-02)
To report the final height (FH) of 76 patients with Turner syndrome (TS). Review of the files and calculation of z scores: of target height (TH), and FH according to NCHS/CDC/2000 and FH according to Lyon and cols. Patients were
Maren Breithaupt et al.
Current rheumatology reports, 15(5), 329-329 (2013-03-27)
Degenerative mechanisms such as protein accumulation and vacuolar transformation in the skeletal muscle distinguish inclusion body myositis (IBM) from other inflammatory myopathies. IBM is particularly common in patients over the age of 50 years and inevitably leads to progressive muscle weakness
Comments on 'Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome' by Zeger et al., pp. 39-47, this issue.
Leonie A Menke et al.
Hormone research in paediatrics, 75(1), 47-48 (2010-11-06)
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service